For the quarter ending 2026-03-31, NRXPW made $1,068K in revenue. -$1,430K in net income. Net profit margin of -133.90%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net patient service revenue | 1,068 | 499* | 242 | - |
| Cost of patient services | 631 | 214* | 97 | - |
| Research and development | 1,309 | 153* | 1,429 | 987 |
| Selling, general and administrative | 3,813 | 4,556* | 2,808 | - |
| Depreciation and amortization | 63 | -8* | 26 | - |
| Settlement expense (income) | -6 | 177* | -94 | 0 |
| General and administrative | - | - | - | 2,743 |
| Total operating expenses | 5,810 | 5,092* | 4,266 | 3,730 |
| Loss from operations | -4,742 | -4,593* | -4,024 | -3,730 |
| Convertible note default penalty | - | 0* | 0 | 0 |
| Interest income | 5 | 6* | 2 | 2 |
| Interest expense | 233 | 671* | 0 | 0 |
| Change in fair value of convertible debt | 0 | -6,661* | 1,502 | 5,565 |
| Change in fair value of warrant liabilities | -3,538 | -20,167* | 4,963 | 6,414 |
| Loss on issuance of registered direct offering | 0 | -730* | 0 | 0 |
| Loss on consideration shares and warrants | 0 | -1,277* | 0 | 0 |
| Loss on convertible note conversions | 0 | -2,232* | -772 | -1,874 |
| Income from equity method investment | 2 | -9* | - | - |
| Loss on exercise of warrants | - | -10,738* | 5,369 | - |
| Total other expense (income), net | 3,312 | 11,178* | -1,866 | -13,851 |
| Net gain | -1,430 | 6,585 | -5,890 | -17,581 |
| Change in fair value of convertible note attributed to credit risk | - | - | 0 | - |
| Other comprehensive loss | - | - | 0 | - |
| Comprehensive loss | - | - | -5,890 | - |
| Basic EPS | -0.04 | 0.274 | -0.27 | -0.98 |
| Basic Average Shares | 32,325,323 | 24,039,675 | 22,231,178 | 17,934,196 |
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)